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The identification of the causative mutation for a 
Mendelian disease enables molecular diagnosis and 
carrier testing in the patient and his or her family. This is 
of great importance for patient management and family 
counseling, and serves as a starting point for therapeutic 
interventions [1]. Furthermore, the identification of 
Mendelian disease genes contributes to our 
understanding of gene functions and biological pathways 
underlying health and disease in general [2], and lessons 
learned from rare diseases are often also relevant to 
common disease [3]. Research aimed at the identification 
of genes that cause Mendelian disease has received a 
boost over the past couple of years by the introduction of 
new technologies that enable the sequencing of DNA at a 
much higher throughput and at much lower costs than 
previously possible [4].
Although traditional gene mapping approaches (such 
as karyotyping [5], linkage analysis [6] homozygosity 
mapping [7] and copy number variation (CNV) analysis 
[8]) have led to great insights into Mendelian disease over 
the past few decades (Figure 1), they are unable to detect 
all forms of genomic variation (Table 1). The approach 
applied is dependent on whether the disease is, for 
example, caused by single nucleotide mutations or by 
CNVs, which is difficult to predict in advance. In 
addition, mapping approaches would often not reduce 
the number of candidate genes sufficiently for 
straightforward follow-up by Sanger sequencing [9]. For 
example, genome-wide single nucleotide polymorphism 
analysis in a large Dutch pedigree with autosomal-
dominant familial exudative vitreoretinopathy (FEVR, 
MIM 613310), a retinal disorder, identified a linkage peak 
of about 40 Mb on chromosome 7, containing more than 
300 genes [10]. Even after adding linkage data from a 
second FEVR family the region was still too large for 
straightforward disease-gene identification, and Sanger 
sequencing of a few candidate genes did not identify 
causative mutations. Next generation sequencing (NGS) 
has the potential to identify all kinds of genetic variation 
at base-pair resolution throughout the human genome in 
a single experiment. This can be performed much faster 
and more cost efficiently than with traditional techniques 
(the sequencing of a genome by traditional techniques 
needed many years and cost millions of dollars, whereas 
NGS technology can sequence a genome for less than 
$7,000 and within a week [11]). This enables the detailed 
genomic analysis of large numbers of patients [12]. In the 
case of the two families with FEVR, we [10] used next 
generation sequencing to investigate the entire coding 
sequence of the 40-Mb region in a single affected 
individual from the first family and identified mutations 
in tetraspanin 12 (TSPAN12) to be the cause of FEVR in 
both families and in three additional families. For most 
Mendelian disorders, however, there is no disease locus 
known and an unbiased approach is required.
There are two unbiased sequencing approaches for 
detecting genetic variation within an individual: whole 
genome sequencing and whole exome sequencing. 
Whole genome sequencing is the ultimate approach for 
detecting all genomic variation in a patient’s genome in a 
single experiment. However, current NGS instruments 
are limited in terms of throughput and cost efficiency. 
Therefore, this approach is limited to gene discovery 
projects in large genome sequencing centers and service 
companies. More cost-efficient sequencing strategies 
have been developed to study the approximately 1% of 
our genome that is protein-coding (the exome), by using 
various capturing approaches to enrich before NGS. 
Exome sequencing has rapidly become one of the main 
tools for studying the genetic causes of Mendelian disease 
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Figure 1. A timeline illustrating technological breakthroughs and hallmark publications for Mendelian disease gene identification.  
(a) The main historical events leading up to the introduction of whole exome sequencing (WES). The vast majority of all Mendelian disease genes 
known so far have been identified using conventional methods, including linkage analysis [6,57-59], homozygosity mapping [7], karyotyping [60] 
and copy number variation (CNV) detection [8,61,62]. Many studies following the initial descriptions have been based on technical achievements, 
such as the first human linkage map [63] or the first draft of the human genome [11,64]. The next generation sequencing (NGS) era was accelerated 
by the first commercial release of an NGS instrument [65], and using the same technology the first individual human genome was sequenced 
by NGS [66]. (b) The main exome sequencing events and landmark publications. More than 30 Mendelian disease genes have been identified by 
exome sequencing so far. Exome sequencing is now the tool of choice for Mendelian disease gene identification, starting with the proof of concept 
[67] and identification of the first recessive [14] and dominant disease genes [29]. It has been shown that linkage and homozygosity information 
can be retrieved directly from exome sequencing data, allowing the application for traditional mapping approaches [53,68]. Abbreviations: ID, 
intellectual disability; RFLP, restriction fragment length polymorphism; STS, sequence-tagged site; WGS, whole genome sequencing.
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[13] because academic groups with access to only one or 
two NGS systems can use this approach to study the 
exomes of hundreds of patients with Mendelian diseases 
per year and the bioinformatic challenges are modest 
when compared with whole genome sequencing. 
Although sequencing a complete genome may take only 1 
week on a single machine, one can sequence more than 
20 exomes in the same time. Since November 2009, 
exome sequencing has led to the identification of over 30 
new genes in Mendelian diseases (Table 2) [14,15]. 
Although publication bias makes it difficult to assess the 
actual success rate of these approaches, from our own 
studies we estimate that whole exome sequencing 
identifies the major disease gene in at least 50% of the 
projects focused on rare but clinically well-defined 
Mendelian diseases (our unpublished data). The rapid 
expansion of Mendelian disease genes by exome 
sequencing is providing new insights because 
technological limitations have probably biased our 
current knowledge. Here, we discuss how our view of 
Mendelian disease is changing as a result of whole exome 
sequencing experiments and a limited number of whole 
genome sequencing approaches.
Lessons learned from exome sequencing
In the past 2 years we have seen many proof-of-concept 
studies using exome or genome studies to identify new 
disease genes for recessive and dominant disorders. 
These publications paint a mixed picture of phenotypes, 
genes and mutations underlying Mendelian disease 
(Figure 1, Table 2). There is a bias towards recessive 
disorders as their genetic causes are easier to identify 
than those that cause dominant disorders. This is because 
genes carrying rare homozygous or compound 
heterozygous variants are not frequent in the unaffected 
population, and these can easily be prioritized for follow-
up. In addition, past sample collection has mainly focused 
on familial cases with recessive inheritance.
Improving clinical diagnosis
From a review of the Mendelian diseases studied (Table 2), 
it is clear that not every whole exome sequencing experi-
ment will result in the identification of a new disease gene. 
There are several examples in which the underlying genetic 
cause was not evident from the phenotype, yet whole 
exome sequencing revealed mutations in a known disease 
gene. For example, Choi et al. [16] identified mutations in 
the gene solute carrier family 26, member 3 (SLC26A3), 
encoding an epithelial Cl−/HCO3− exchanger, in a case with 
the initial differential diagnosis of Bartter syndrome, a 
renal salt-wasting disease. After these mutations were 
identified the clinical diagnosis was re-evaluated and 
changed to congenital chloride diarrhea (CLD, MID 
214700), a disease that was already known to result from 
mutations in this gene [17]. Similarly, Worthey et al. [18] 
reported a case in which a diagnosis of intractable 
inflammatory bowel disease (MIM 266600) was initially 
missed but was revealed after the identifi cation of a 
missense mutation in XIAP, the X-linked inhibitor of 
apoptosis gene, by exome sequencing. Both these examples 
[16,18] show that unbiased whole exome sequencing can 
have an enormous impact on patient management by 
assisting clinicians in making the proper diagnosis, a 
phenomenon known as reverse phenotyping [19].
Mutations in genes that are known to cause disease will 
also be identified frequently when whole exome or 
Table 1. Mendelian disease gene identification approaches
Approach Applies to Advantages Disadvantages
Candidate gene Any disease Easy to perform for one or two genes; requires 
no mapping, can directly identify the causative 
variant/mutation
Relies heavily on current biological knowledge; success 
rate very low
Genetic mapping by 
karyotyping
Any disease Easy to perform; no familial cases required; can 
detect (large) balanced events
Low resolution, only detects large chromosomal 
aberrations; mutation detection requires second step
Genetic mapping by linkage 
analysis
Inherited disease Easy to perform Requires large families, often identifies large loci; 
mutation detection requires second step
Genetic mapping by 
homozygosity mapping
Recessive 
monogenic 
diseases
Small families can be used Most useful for consanguineous families; often identifies 
large loci; mutation detection requires second step
Genetic mapping by CNV 
analysis
Monogenic/
monolocus  
disease
High resolution CNV screening; no familial 
cases required; can potentially identify small 
loci
Only investigates CNVs; cannot detect balanced events, 
no base-pair resolution; mutation detection requires 
second step
Whole exome sequencing 
(WES)
Any disease Base-pair resolution exome-wide; detects most 
types of genomic variation; can directly identify 
the causative variant/mutation
Unable to detect non-coding variants; limited resolution 
for CNVs and other structural variation; coverage 
variability due to enrichment process; relatively expensive
Whole genome sequencing 
(WGS)
Any disease Base-pair resolution genome-wide; detects all 
types of genomic variation; can directly identify 
the causative variant/mutation
Data analysis complex; even more expensive than exome 
sequencing
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genome sequencing is applied to genetically 
heterogeneous diseases that can be caused by monogenic 
mutations in many different genes. The technological 
limitations of Sanger sequencing often did not allow 
routine analysis of all known disease genes in patients 
with genetically heterogeneous disorders before whole 
exome approaches. The most prominent example of this 
was the identification of mutations in the SH3 domain 
and tetratricopeptide repeat domain 2 gene (SH3TC2, a 
gene known to cause neuropathy) as the cause of 
Charcot-Marie Tooth neuropathy (MIM 601596) in a 
family by whole genome sequencing [20]. An unbiased 
base-pair resolution approach can also reveal mutations 
in multiple genes that jointly explain a combination of 
two Mendelian phenotypes. For example, a study 
identified mutations in dihydroorotate dehydrogenase 
(DHODH) and dynein, axonemal, heavy chain 5 
(DNAH5) in two siblings as the explanation of the 
combined phenotype of Miller syndrome (postaxial 
acrofacial dysostosis; MIM 263750) and primary ciliary 
dyskinesia, respectively [14]. Traditional mapping 
approaches would probably have missed the mutations in 
DNAH5 as these were unique to this sibling and not 
present in other patients with Miller syndrome, which 
severely complicates mapping. Unbiased whole exome 
sequencing, on the other hand, identifies all variants and 
Table 2. Mendelian disease gene identifications by exome or genome sequencing
Disorder Inheritance Gene identified Scope References
Congenital chloride diarrhea Recessive SLC26A3	 Exome Choi et	al.	[16]
Miller syndrome Recessive  DHODH	 Exome Ng et	al.	[14]
Charcot-Marie-Tooth neuropathy Recessive SH3TC2	 Genome Lupski et	al.	[20]
Metachondromatosis Dominant PTPN11	 Genome Sobreira et	al.	[23]
Schinzel-Giedion syndrome Dominant SETBP1	 Exome Hoischen et	al.	[29]
Nonsyndromic hearing loss Recessive GPSM2	 Exome Walsh et	al.	[69]
Perrault syndrome Recessive HSD17B4	 Exome Pierce et	al.	[25]
Hyperphosphatasia mental retardation syndrome Recessive PIGV	 Exome Krawitz et	al.	[68]
Sensenbrenner syndrome Recessive WDR35	 Exome Gilissen et	al.	[26]
Cerebral cortical malformations Recessive WDR62	 Exome Bilguvar et	al.	[70]
Kaposi sarcoma Recessive STIM1	 Exome Byun et	al.	[71]
Spinocerebellar ataxia Dominant TGM6	 Exome Wang et	al.	[72]
Combined hypolipidemia Recessive ANGPTL3	 Exome Musunuru et	al.	[40]
Complex I deficiency Recessive ACAD9	 Exome Haack et	al.	[52]
Autoimmune lymphoproliferative syndrome Recessive FADD	 Exome Bolze et	al.	[73]
Amyotrophic lateral sclerosis Dominant VCP	 Exome Johnson et	al.	[74]
Nonsyndromic mental retardation Dominant Various Exome Vissers et	al.	[31]
Kabuki syndrome Dominant MLL2	 Exome Ng et	al.	[30]
Inflammatory bowel disease Dominant XIAP	 Exome Worthey et	al.	[18]
Nonsyndromic mental retardation Recessive TECR	 Exome Caliskan et	al.	[75]
Retinitis pigmentosa Recessive DHDDS	 Exome Züchner et	al.	[56]
Osteogenesis imperfecta Recessive SERPINF1	 Exome Becker et	al.	[53]
Dilated cardiomyopathy Dominant BAG3	 Exome Norton et	al.	[24]
Hajdu-Cheney syndrome Dominant NOTCH2	 Exome Simpson et	al.	[76]
Hajdu-Cheney syndrome Dominant NOTCH2	 Exome Isidor et	al.	[77]
Skeletal dysplasia Recessive POP1	 Exome Glazov et	al. [78]
Amelogenesis Recessive FAM20A	 Exome O’Sullivan et	al.	[80]
Chondrodysplasia and abnormal joint development Recessive IMPAD1	 Exome Vissers et	al.	[80]
Progeroid syndrome Recessive BANF1	 Exome Puente et	al.	[81]
Infantile mitochondrial cardiomyopathy Recessive AARS2	 Exome Götz et	al.	[82]
Sensory neuropathy with dementia and hearing loss Dominant DNMT1	 Exome Klein et	al.	[49]
Autism Dominant Various Exome O’Roak et	al.	[32]
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allows for detailed analysis of individual cases and 
families. This is advantageous because the clinical 
spectrum of a disease can often be wider than previously 
appreciated, and multiple mutations might jointly explain 
a more complex phenotype.
Phenotypic heterogeneity
Allelic heterogeneity, in which a disease can be caused by 
mutations in different genes, has long been recognized to 
occur in Mendelian diseases. For example, in the case of 
Fanconi anemia (MIM 227650), a myelodysplastic 
disorder with chromosome breakage affecting all bone 
marrow elements and associated with cardiac, renal and 
limb malformations, mutations in many genes give rise to 
the exact same phenotype [21]. Conversely, it is also clear 
that different mutations in the same gene can result in 
completely different phenotypes, as is the case for tumor 
protein p63, in which different mutations can lead to 
several monogenic malformation syndromes [22]. This 
extreme form of phenotypic variability suggests 
completely different biological pathways are involved.
Unbiased whole exome and/or genome sequencing has 
identified further examples of unrelated phenotypes 
caused by different mutations in the same gene. Sobreira 
et al. [23] sequenced the complete genome of a single 
patient with metachondromatosis (MIM 156250), a 
skeletal dysplasia. They identified pathogenic loss-of-
function mutations in protein tyrosine phosphatase, 
nonreceptor-type 11 (PTPN11) for which gain-of-
function mutations are known to cause Noonan 
syndrome (MIM 163950), characterized by short stature 
and facial features, and pulmonary stenosis. Another 
example comes from Norton et al. [24], who identified 
both truncating and missense mutations in Bcl2-
associated athanogene 3 (BAG3) in patients with dilated 
cardiomyopathy (MIM 115200), characterized by cardiac 
dilatation and reduced systolic function. A missense 
variant in this gene was previously known to cause 
myofibrillar myopathy (MIM 612954), a strikingly 
different phenotype characterized by skeletal muscle 
weakness associated with cardiac conduction blocks, 
arrhythmias, and restrictive heart failure. The authors 
[24] also observed phenotypic variability in a zebrafish 
model, where translation initiation blocking of the whole 
gene gave a single phenotype of heart failure. By contrast, 
a second morpholino oligonucleotide that splices out 
exon 2 resulted in axis curvature that might be analogous 
to skeletal myopathy. This observation led the authors 
[24] to suggest fundamental differences in mechanisms of 
disease. Similarly, Pierce et al. [25] observed mutations in 
HSD174B, which encodes 17β-hydroxysteroid 
dehydrogenase type 4, in two adult patients with Perrault 
syndrome, characterized by ovarian dysgenesis and 
deafness. Different classes of HSD17B4 mutations have 
previously been associated with three different types of 
D-bifunctional protein (DBP) deficiency (MIM 261515), 
which is generally fatal within the first 2 years of life. The 
authors [25] suggested that the specific mutations they 
identified lead to a much milder phenotype that allows 
patients to survive to puberty and causes ovarian 
dysgenesis in females in addition to the known 
neurological defects associated with DBP. Using 
traditional approaches, these genes might not have been 
considered likely candidates for the disease.
In addition, for some novel disease genes the type of 
mutation may be specific to the disease in which these 
were observed. In two patients with Sensenbrenner 
syndrome, an autosomal recessive disorder characterized 
by ectodermal features, craniosynostosis and hypodontia, 
whole exome sequencing revealed a missense and a 
nonsense mutation in WD-repeat-containing protein 35 
(WDR35) [26]. It may well be that two missense 
mutations result in a milder phenotype, whereas other 
mutations could result in a more severe phenotype, as 
confirmed by a subsequent study of patients with a lethal 
short rib polydactyly syndrome [27].
The role of de novo mutations in rare and common 
disorders
Many dominant Mendelian disorders occur sporadically 
because the severity and early onset of the disorder 
preclude transmission to subsequent generations. 
Consequently, there are no families available for genetic 
studies. Genetic variants associated with these diseases 
are under strong negative selection and will be rapidly 
eliminated from the genetic pool [28]. For these reasons, 
many genes that cause ‘sporadic’ disease remain to be 
identified. Important new insights have come from 
studying these sporadic forms of Mendelian disease by 
whole exome sequencing.
Exome sequencing first identified de novo mutations 
causing rare syndromic forms of dominant sporadic 
Mendelian disease, such as Schinzel-Giedion syndrome 
(MIM 269150) and Kabuki syndrome (MIM 147920) 
[29,30]. Both disorders are characterized by intellectual 
disability and typical facial features, and were anticipated 
to be largely caused by mutations in a single gene, which 
facilitated interpretation of exome sequencing data. 
Multiple unrelated patients with the same syndrome 
were sequenced and variant prioritization was focused 
on genes showing severe mutations in multiple if not all 
patients. For Schinzel-Giedion syndrome this resulted in 
the identification of heterozygous mutations in SETBP1 
(encoding the SET binding protein 1, a histone-lysine N-
methyltransferase) in 12 out of 13 patients tested [29]. All 
mutations in SETBP1 occurred de novo in the patient and 
were not detected in DNA from the unaffected parents. 
The disease mutations clustered in a genomic stretch of 
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just 11 nucleotides, affecting three of four consecutive 
amino acids. Interestingly, individuals with partial 
chromosome 18 deletions affecting SETBP1 do not show 
clinical overlap with Schinzel-Giedion syndrome. 
Collectively, this indicates that these mutations are likely 
to confer a gain of function. Exome sequencing is 
particularly useful for identifying these types of 
mutations for which no other genome-wide approach is 
applicable. We suspect that gain-of-function mutations 
are largely underrepresented in the current databases, 
and that many more will be detected by exome 
sequencing.
After the detection of de novo mutations in rare 
Mendelian disorders, subsequent studies focused on 
their roles in common neurodevelopmental disorders, 
such as intellectual disability [31] and autism (MIM 
209850) [32]. The high population frequency of these 
disorders has been hypothesized to reflect de novo 
mutations that compensate for allele loss due to severely 
reduced fecundity. If this were the case, the frequency of 
these disorders would reflect the size of the mutational 
target; disease caused by de novo mutations in a single 
gene will be very rare, whereas disorders caused by de 
novo mutations in many genes can occur at a high 
prevalence (Figure 2). In other words, the complexity of 
many common diseases might be primarily due to genetic 
heterogeneity, with novel defects in different genes 
causing the same disease [33]. This would explain both 
the genetic and the clinical heterogeneity observed for 
mental illnesses and would explain why these disorders 
have a low recurrence risk [34]. To investigate this 
hypothesis, Vissers et al. [31] sequenced the exome of ten 
patients with intellectual disability and their healthy 
parents. After filtering out all inherited genomic 
variation, nine de novo mutations were identified in ten 
patients, between none and two per patient. Two de novo 
mutations were observed in genes previously linked to 
intellectual disability, and an analysis of the gene function 
and the mutation type indicated that an additional four 
de novo mutations in novel genes are likely to be 
pathogenic.
Similar results were recently reported by O’Roak et al. 
[32], who studied 20 patients with sporadic autism using 
the same approach [32]. Related work has also been 
reported for patients with schizophrenia (MIM 181500), 
although not yet using unbiased whole genome or exome 
approaches. In this case the authors [32] performed 
Sanger sequencing for 401 synapse-expressed genes in 
143 patients with schizophrenia and identified eight de 
novo mutations, two of which were in SH3 and multiple 
Figure 2. A representation of the relationship between the size of the mutational target and the frequency of disease for disorders 
caused by de novo mutations. Dashed lines separate different sizes of mutational target. Rounded rectangles represent examples of genes. 
Disease frequency categories range from extremely rare disorders (that is, only a few cases described) to disorders that occur more commonly 
within the population (such as intellectual disability, which has a frequency in the general population of more than 1%). Underneath each of these 
categories an example disorder is given. The lower part shows some of the implicated disease gene(s), ranging from a specific domain in a single 
gene, to single gene disorders, to multiple gene disorders, to disorders with extreme genetic heterogeneity. From left to right: SET binding protein 1 
(SETBP1); dihydroorotate dehydrogenase (DHODH); NADH dehydrogenase (ubiquinone) Fe-S protein 1 (NDUFS1); acyl-CoA dehydrogenase family, 
member 9 (ACAD9); jumonji, AT rich interactive domain 1C (JARID1C); capicua homolog (CIC); deformed epidermal autoregulatory factor 1 (DEAF1); 
YY1 transcription factor (YY1); dynein, cytoplasmic 1, heavy chain 1 (DYNC1H1); member RAS oncogene family (RAB39B); synaptic Ras GTPase 
activating protein 1 (SYNGAP1).
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ankyrin repeat domains 3 (SHANK3), a gene known to 
cause schizophrenia [35,36]. If confirmed in larger 
follow-up studies, this would indicate that a significant 
proportion of these common disorders is caused by rare 
de novo mutations. This would provide strong support for 
the hypothesis that rare variants substantially contribute 
to common diseases and would also represent a change 
of focus in Mendelian genetic disease research, where the 
emphasis has been on studying familial forms of disease.
Severe early onset disorders, such as intellectual 
disability, autism and childhood schizophrenia, are 
clearly the first group of disorders on which to test this de 
novo mutation hypothesis, as inherited mutations are less 
likely to have a major role in these disorders because of 
the reduced fitness of those affected by the disease [37]. 
The contribution of de novo mutations to adult-onset 
diseases with less impact on fertility is expected to be 
lower. However, we note that this is mainly dependent on 
the size of the mutational target and remains to be 
determined. A problem in this respect, however, is the 
availability of surviving parents of offspring who have a 
late-onset disease in order to prove de novo occurrence 
[38]. Related to this, Conrad et al. [39] recently published 
the first genome sequencing study in two healthy trios of 
offspring with both their parents and validated 49 de 
novo germline mutations in one offspring and 35 in the 
other. This study [39] also highlighted the fact that cell 
lines are not the preferred material for this analysis, as 
952 and 643 non-germline de novo mutations were 
observed in both offspring that are likely to have been 
caused by cell line creation and culturing. Given the 
apparent role of rare de novo mutations in disease, it is 
evident that we need to learn much more about the 
general occurrence of these mutations in our population 
and perform detailed comparisons of de novo mutations 
in patients versus controls.
Finding the Mendelian contribution to common traits
Although some studies support the arguments that a 
significant proportion of common disorders (such as 
intellectual disability, autism and schizophrenia) 
represent an accumulation of rare disorders, true 
multigenic/complex diseases can also benefit from exome 
sequencing. Until NGS studies of the size of genome-
wide association studies are broadly applicable and 
affordable (that is, until one can run and analyze 1,000 
exomes routinely), insights can be obtained by studying 
small cohorts from the extreme ends of the phenotypic 
spectrum of common traits, because the Mendelian 
forms of these traits are expected to be overrepresented 
in this group. The first example of this approach was 
provided by whole exome sequencing in patients with 
extremely low low-density lipoprotein (LDL) cholesterol 
levels, which identified mutations in ANGPTL3 [40]. The 
identified gene is secreted and expressed primarily in the 
liver and encodes the angiopoietin-like 3 protein. 
ANGPTL3 has a role in lipoprotein lipase and endothelial 
lipase inhibition, thereby increasing plasma triglyceride 
and high-density lipoprotein (HDL) cholesterol levels. 
The very low LDL levels in these individuals could 
therefore be explained by two mutated alleles for this 
gene.
From genes to pathways
Although only a few exome studies have been conducted 
so far (Table 2), these have already provided new insights 
into human gene networks. For example, it was known 
through classical disease gene identification that histone 
modifiers have an important role in human develop-
mental diseases. Haploinsufficiency of histone methyl-
trans ferases, such as NSD1 (encoding nuclear receptor 
binding SET domain protein 1), NSD2 (encoding nuclear 
SET domain-containing protein 2 and also called Wolf-
Hirschhorn syndrome candidate 1, WHSC1) and EHMT1 
(encoding euchromatic histone-lysine N-methyltransferase 
1), cause several congenital diseases [41]. Exome sequencing 
studies have confirmed the importance of this class of 
genes. Among the few exome studies that identified 
dominant genes for Mendelian disorders, three disease 
genes function in histone modification: (i) mutations in 
the histone methyltrans ferase gene MLL2 (H3K4me) 
have been shown to be the cause of Kabuki syndrome 
[30]; (ii) point mutations in SETBP1 – encoding the SET 
binding protein 1, a histone-lysine N-methyltransferase – 
have been identified as the cause of Schinzel-Giedion 
syndrome [29]; (iii) most recently, ASXL1, encoding the 
protein Additional sex-combs-like 1, was implicated in 
Bohring-Opitz syndrome (MIM 605039), characterized 
by severe malformations and intellectual disability [42]. 
ASXL1 is an interactor of lysine-specific demethylase 1 
(LSD1) and therefore ASXL1 can be considered another 
histone modification gene [43].
Histone modifiers might have a dual role in disease. 
Although germline mutations in these genes can lead to 
developmental disorders, somatic mutations have been 
reported in leukemias and other malignancies. 
Translocations of NSD1 to NUP98 (encoding nucleoporin 
98 kDa) and of NSD2/WHSC1 to IgH occur in some 
hematologic malignancies [41]. In addition, SETBP1 
translocations with NUP98 have been described in 
pediatric acute T-cell lymphoblastic leukemia [44], and 
somatic mutations in ASXL1 occur in several forms of 
leukemia [45,46]. Further credence for this dual role for 
genes involved in histone modification has been given by 
recent studies. It was already anticipated that the 
DNMT3A, DNMT3B and DNMT3L proteins were 
primarily responsible for the establishment of genomic 
DNA methylation patterns and should therefore have an 
Gilissen et al. Genome Biology 2011, 12:228 
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important role in human developmental, reproductive 
and mental health [47]. Exome sequencing identified 
DNMT3A (encoding DNA methyltransferase 3A) 
mutations in monocytic leukemia, confirming the 
suspected link with cancer development [48]. Exome 
sequencing also led to the identification of mutations in 
DNMT1 that cause both central and peripheral 
neurodegeneration in a form of hereditary sensory and 
autonomic neuropathy with dementia and hearing loss 
[49]. These exome sequencing findings add to a growing 
list of genes for which somatic mutations have been 
identified in malignancies and germline mutations in 
developmental disorders.
The importance of evolutionary conservation
The interpretation of missense variants in Mendelian 
diseases is challenging. A common method to address 
pathogenicity is to assume that purifying selection 
‘constrains’ evolutionary divergence at phenotypically 
important nucleotides and amino acids [50]. Following 
an earlier suggestion [51], exome studies have now 
confirmed that pathogenic missense variants indeed tend 
to affect highly conserved nucleotides (using GERP, 
PhyloP or PhastCons scores), or amino acids (by multiple 
sequence alignment). All scores in some way measure the 
difference between the number of nucleotide 
substitutions that have occurred at a site during evolution 
and the number of substitutions that are expected from 
neutral evolution. As an example, the nucleotides 
affected by de novo mutations in SETBP1 that cause 
Schinzel-Giedion syndrome are among the most highly 
conserved bases in the genome, according to PhyloP 
vertebrate conservation scores [29]. This observation is 
unlikely to be explained by an ascertainment bias, as 
evolutionary conservation is generally used only to 
strengthen the existing evidence of pathogenicity, rather 
than to prioritize variants for follow-up.
Towards therapy for Mendelian disease
Exome studies have revealed mutations causing 
Mendelian disease in more than 30 genes, many of which 
had no previously known function. This knowledge can 
help to identify essential biological pathways disrupted in 
these often severe disorders. For example, Haack et al. 
[52] obtained a promising clinical response to a 
multivitamin scheme including daily riboflavin treatment 
in a patient with a complex 1 deficiency (MIM 252010) 
after whole exome sequencing revealed mutations in 
ACAD9, a member of the mitochondrial acyl-CoA 
dehydrogenase protein family. Another example involves 
SERPINF1, in which mutations were detected by whole 
exome sequencing in patients with osteogenesis 
imperfecta [53]. There is much to learn from the first 
gene therapy trials with pigment epithelium-derived 
factor (PEDF, encoded by SERPINF1). PEDF is thought to 
counteract the effect of vascular endothelial growth 
factor (VEGF) – a signal protein produced by cells that 
stimulates vasculogenesis and angiogenesis – and trials 
are dedicated to the treatment of the wet form of age-
related macular degeneration [54]. In a mouse model of 
ischemia-induced retinal angiogenesis, PEDF eliminated 
aberrant neovascularization [55], which suggests that 
PEDF might have potential in treating osteogenesis 
imperfecta. Finally, Züchner et al. [56] used whole exome 
sequencing to identify mutations in dehydrodolichyl 
diphosphate synthase (DDHDS) in patients with retinitis 
pigmentosa, linking this disease to N-linked glycosylation 
pathways, suggesting new possibilities for therapeutic 
interventions. Although the number of these promising 
examples is small, one might foresee that several clinical 
conditions will be better understood after the 
identification of the underlying disease gene, and in some 
cases this will enable usable therapy.
Conclusions
Exome sequencing and, in a few cases, genome 
sequencing, has significantly progressed the field of 
Mendelian disease in the past 2 years. The unbiased 
nature of these approaches is providing significant 
insights into the genetic causes of Mendelian disease in 
general, and of sporadic disease in particular, by revealing 
rare de novo mutations as a common cause of disease. 
This approach is crucial for drawing accurate genotype-
phenotype correlations and will undoubtedly improve 
diagnosis for the millions of individuals with Mendelian 
disease, improve family counseling and reveal new 
therapeutic targets. The next challenge in disease 
research will be to systematically study the role of 
variation in the non-coding part of our genome in health 
and disease. The study of Mendelian diseases will be 
crucial in this endeavor, as they offer the advantage of 
high penetrant mutations, the ability to perform family 
studies and look for segregation of variation with disease, 
and the possibility of finding recurrent mutations in 
unrelated patients with similar phenotypes.
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